Emergent BioSolutions (STU:ER4) LT-Debt-to-Total-Asset : 0.25 (As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Emergent BioSolutions LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Emergent BioSolutions's long-term debt to total assests ratio for the quarter that ended in Mar. 2024 was 0.25.

Emergent BioSolutions's long-term debt to total assets ratio increased from Mar. 2023 (0.15) to Mar. 2024 (0.25). It may suggest that Emergent BioSolutions is progressively becoming more dependent on debt to grow their business.

Emergent BioSolutions LT-Debt-to-Total-Asset Historical Data

The historical data trend for Emergent BioSolutions's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Emergent BioSolutions LT-Debt-to-Total-Asset Chart

Emergent BioSolutions Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.34

0.29

0.27

0.14

0.25

Emergent BioSolutions Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.15	0.21	0.24	0.25	0.25

Emergent BioSolutions LT-Debt-to-Total-Asset Calculation

Emergent BioSolutions's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	409.44	/	1671.874
	=	0.24

Emergent BioSolutions's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2024 is calculated as

LT Debt to Total Assets (Q: Mar. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2024 )	/	Total Assets (Q: Mar. 2024 )
	=	410.964	/	1659.312
	=	0.25

Emergent BioSolutions (STU:ER4) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Emergent BioSolutions LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Emergent BioSolutions's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Emergent BioSolutions (STU:ER4) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Emergent BioSolutions Inc (STU:ER4) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

EBS:USA ER4:Germany

Address

400 Professional Drive, Suite 400, Gaithersburg, MD, USA, 20879

Website

https://www.emergentbiosolutions.com

Emergent BioSolutions Inc offers public health products to the government and healthcare providers. The company has four main units: vaccines, which produces specialty vaccines for public health threats; devices, such as nasal sprays, skin lotions, and injections; therapeutics, which includes antibody-based treatments; and contract development and manufacturing, which brings treatments to market through collaboration with the pharmaceutical and biotechnology industries and the United States government. Most revenue comes from U.S. government purchases of vaccines, devices, and therapeutic products. The company operates in two reportable segments; the Products Segment and the Services Segment.

Emergent BioSolutions (STU:ER4) Headlines

No Headlines